Tom Graney, Oxurion CEO

May 9, 2022 10:07 AM EDTUpdated 11:03 AM

Belgian eye biotech gets hammered by investors after PhII trial fails efficacy on key endpoints

Paul Schloesser

Associate Editor

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

TIGIT graveyard expands as GSK drops late-stage asset with iTeos

Bayer starts 2025 by cutting 2,000 jobs as it homes in on year-end rehaul target

Some generics, biosimilar drugmakers say they can withstand tariff impact

Arcturus to prioritize mRNA therapeutics in bid to boost rare disease programs

Updated: To spin off or not to spin off? Galapagos backpedals on separation plans, CEO Paul Stoffels exits early

UnitedHealth Group CEO Andrew Witty steps down